Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies

References

• Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980; 23(8)881–888
   PubMed Web of Science ®Google Scholar
• Pachman LM, Miller FW. Idiopathic inflamamtory myopathies: Dermatomyositis, polymyositis and related disorders. Samter's immunologic diseases. Lippincott Williams & Wilkins, Philadelphia 2001; 520–530
   Google Scholar
• Schmidt WA, Wetzel W, Friedlander R, Lange R, Sorensen HF, Lichey HJ, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies—an evolving spectrum of disease manifestations. Clin Rheumatol 2000; 19(5)371–377
   PubMedGoogle Scholar
• Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 2000; 12(6)475–481
   PubMed Web of Science ®Google Scholar
• Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller F, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, et al. Clinical, serological and immunogenetic features of Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40: 1257–1266
   PubMedGoogle Scholar
• Hirakata M, Suwa A, Nagai S, Kron MA, Trieu EP, Mimori T, et al. Identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999; 162(4)2315–2320
   PubMed Web of Science ®Google Scholar
• Mathews MB, Reichlin M, Hughes GR, Bernstein RM. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984; 160(2)420–434
   PubMed Web of Science ®Google Scholar
• Bunn CC, Bernstein RM, Mathews MB. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med 1986; 163(5)1281–1291, May 1
   PubMed Web of Science ®Google Scholar
• Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 1990; 144(5)1737–1743, Mar 1
   PubMed Web of Science ®Google Scholar
• Miller FW, Waite KA, Biswas T, Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci USA 1990; 87(24)9933–9937
   PubMedGoogle Scholar
• Nishikai M, Ohya K, Kosaka M, Akiya K, Tojo T. Anti-Jo-1 antibodies in polymyositis or dermatomyositis: Evaluation by ELISA using recombinant fusion protein Jo-1 as antigen. Br J Rheumatol 1998; 37(4)357–361
   PubMedGoogle Scholar
• Peene I, Meheus L, Veys EM, De Keyser F. Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 2001; 60(12)1131–1136
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (in two parts). N Engl J Med 1975; 292: 403
   PubMed Web of Science ®Google Scholar
• Wortmann RL. Inflamatory diseases of muscle and other myopathies. Kelley's Textbook of Rheumatology. W.B. Saunders Co., Philadelphia 2001
   Google Scholar
• Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: Epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 2002; 28(4)723–741, Nov
   PubMed Web of Science ®Google Scholar
• Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50(1)209–215
   PubMedGoogle Scholar
• Franceschini F, Cavazzana I, Generali D, Quinzanini M, Viardi L, Ghirardello A, et al. Anti-ku antibodies in connective tissue diseases: Clinical and serological evaluation of 14 patients. J Rheumatol 2002; 29(7)1393–1397
   PubMedGoogle Scholar
• Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991; 70(6)360–374
   PubMed Web of Science ®Google Scholar
• Veeraraghavan S, Nicholson AG, Wells AU. Lung fibrosis: New classifications and therapy. Curr Opin Rheumatol 2001; 13(6)500–504
   PubMedGoogle Scholar
• Chwalińska-Sadowska H, Małdykowa H. Polymyositis/dermatomyositis: 25 years follow-up of 50 patients. Disease course, treatment, prognostic factors. Materia Medica Polona 1990; 75(3)213
   Google Scholar
• Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998; 41(7)1215–1220, July
   PubMed Web of Science ®Google Scholar
• Cronin ME, Miller FW, Hicks JE, Dalakas M, Plotz PH. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989; 16: 1225–1228
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47(6)614–622
   PubMedGoogle Scholar
• Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: Clinical course and response to treatment. Semin Arthritis Rheum 2003; 32(5)273–284
   PubMed Web of Science ®Google Scholar
• Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M, et al. Cyclosporin a and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002; 61: 37–42
   PubMed Web of Science ®Google Scholar
• Grau JM, et al. Cyclosporin a as first choice for dermatomyositis. J Rheumatol 1994; 21: 381
   PubMed Web of Science ®Google Scholar
• Bunch TW. Prednisone and azathioprine for polymyositis. Arthritis Rheum 1981; 24: 45–48
   PubMed Web of Science ®Google Scholar
• Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. Cyclosporine a versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000; 29: 95–102
   PubMed Web of Science ®Google Scholar